Physician profile
Britni Layne-Gardiner Johnson
NPI 1881375723
$23,887.15
in general payments reported to CMS, 2019-2025
48 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,537 · 2024: $6,491 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $7,631 · Travel and Lodging: $3,122 · Consulting Fee: $2,473 · Education: $33.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,628.50 |
| Food and Beverage | $7,631.24 |
| Travel and Lodging | $3,121.79 |
| Consulting Fee | $2,472.50 |
| Education | $33.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $10,398.99 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $4,088.21 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $2,974.38 | 2023-2025 | |
| Abbvie INC. | $716.53 | 2024-2025 | |
| Tg Therapeutics, INC. | $676.83 | 2023-2025 | |
| Ucb, INC. | $427.83 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Lundbeck LLC | $345.75 | 2023-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $320.79 | 2023-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $299.19 | 2023-2024 | Ultomiris, Soliris |
| Sk Life Science, INC. | $288.15 | 2023-2025 | |
| Argenx US, INC. | $267.17 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $259.63 | 2023-2025 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $255.61 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $250.15 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Jazz Pharmaceuticals INC. | $226.73 | 2023-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britni Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.